Asana BioSciences is led by Dr. Sandeep Gupta, who was previously the Senior Vice-President of Discovery and Early Development, Endo Pharmaceuticals. Prior to Endo, Dr. Gupta spent a decade at Forest Laboratories as Head of Drug Discovery and Pharmacology. He played a key role in the development of several block buster drugs during his tenure at Endo and Forest. Before Forest Laboratories, Dr. Gupta held academic positions at the University of Pennsylvania and Boston University Schools of Medicine. Regarded as an architect of the Virtual Drug Discovery Research model, he has pioneered several successful Discovery and Development collaborations across the globe. He is a co-inventor on multiple patents and has authored over 50 scientific papers, presentations and book chapters.
Sandeep Gupta, PhD
Founder, President & Chief Executive Officer
Louis Denis, MD is a medical oncologist with more than 20 years of academic and industry experience in oncology and clinical cancer drug development, including first-in-human and global registration trials. Dr. Denis held strategic and leadership positions of increasing responsibility in Clinical Development and Medical Affairs at Pfizer and Boehringer-Ingelheim. Dr. Denis earned an MD degree from the Vrije Universiteit Brussels, Belgium, and did his post-doctoral fellowships in Internal Medicine/Medical Oncology at Middelheim Hospital, Antwerp; the Rotterdam Cancer Institute, The Netherlands; and the Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas. He is co-inventor on multiple patents and is co-author of over 30 scientific publications and presentations on cancer clinical research.
Louis Denis, MD
Chief Medical Officer
Niranjan Rao, PhD FCP
Vice President – Clinical Development
Dr. Rao has 30 years of drug development experience in a variety of therapeutic areas at Aventis, Forest Laboratories, Kyowa Hakko Kirin Pharma and Endo Pharmaceuticals. He has held positions of increasing scope and responsibility over the course of his career. He has led early clinical development programs in oncology and has been an important contributor on several NDAs and approved drugs. He is a co-inventor on multiple patents and has published or presented over 60 scientific papers.
Vice President – Chemistry, Manufacturing, and Controls
Shashank Mahashabde has over 30 years of experience in the pharmaceutical industry in Research and Development at Schering Plough Research Institute and Forest Research Institute. He has extensive experience in development of all dosage forms and has been involved in several NDAs and development of 19 products on the market. Most recently, he was President of Business Development and Marketing for North America at Neuland Laboratories Inc. He has several applied and issued patents.
Pablo Jimenez, MD, FAPRC
Vice President – Therapeutic Area Head Immunology
Dr. Jimenez is a Senior pharmaceutical executive physician with more than 20 years of experience in clinical research, regulatory, and medical affairs in the dermatology, rheumatology, and respiratory therapeutic areas. His product business development expertise includes atopic dermatitis, psoriasis, asthma and wound healing. Dr. Jimenez earned an MD degree from the Central University, Ecuador, and did his post-doctoral work at Brown University. He is a fellow of the Academy of Physicians in Clinical Research (FAPCR). He holds a successful track record in executive leadership positions at premier biopharmaceutical and pharmaceutical companies, such as Human Genome Sciences, Novartis, Celsus, and Ziarco. He is co-inventor on multiple patents and is co-author of numerous scientific publications and presentations.
Yusong Chen, PhD
Vice President – Biostatistics and Data Management
Dr. Chen has over 28 years of experience in the pharmaceutical industry at AstraZeneca, GSK, Cephalon, Endo Pharmaceuticals and PAREXEL. His experience extended from innovative, generic, and biosimilar products from Phase I to Phase IV in a variety of therapeutic areas. He was an important contributor of multiple NDAs and approved medical products. He has held variety leadership positions in his career and most recently he was the VP of Center of Excellence/Biostatistics at PAREXEL. His statistical expertise includes modeling and simulation and innovative clinical trial designs.
Tara Chapman, PharmD
Senior Director – Regulatory Affairs
Dr. Chapman has 20 years of experience in the pharmaceutical industry in various therapeutic areas, including respiratory, inflammation, pain, oncology and dermatology. Her strategic regulatory experience ranges from pre-IND through post-marketing activities, including leading or contributing to various IND, NDA, and sNDA filings, Advisory Committee meetings, shared post-marketing requirements and shared REMS programs. Dr. Chapman was most recently Senior Director, Regulatory Affairs at Endo Pharmaceuticals, and previously held positions of increasing responsibility at AstraZeneca and Wyeth (now Pfizer).